SETD2 and lung cancer: Additionally, the paradoxical finding that pre-clinical data demonstrates pro-tumorigenic effects however clinical data thus far has consistently demonstrated more favorable outcomes underscores the need for further investigation into SETD2-mutated lung cancer.